Prof Dunn is a bench scientist, he is not on the list of PI's running the pnoc trial. The article may be referring to trials in NSW sites that he has more connectivity with, rather than all the sites. If Kazia stated that interim data is due in next 3-4 weeks this may represent first 12-20 patients from all sites that have passed primary end points of pfs at 6 months and os at 7 months. There are 30 sites in a study that opened in Oct 21, fair assumption that they would have > 12 patients that have been on drug for more than 7 months. Hopefully it is more patients and some patients data are out to 12 months+. Fingers crossed data is sound enough for a takeover bid.
- Forums
- ASX - By Stock
- KZA
- Ann: Paxalisib receives Fast Track Designation from US FDA
Ann: Paxalisib receives Fast Track Designation from US FDA, page-33
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)